Literature DB >> 10354660

Pimozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine.

J Takhar.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10354660      PMCID: PMC1189016     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  9 in total

1.  Differential modulation of dopamine D2 receptors by chronic haloperidol, nitrendipine, and pimozide.

Authors:  L H Tecott; L L Kwong; S Uhr; S J Peroutka
Journal:  Biol Psychiatry       Date:  1986-10       Impact factor: 13.382

2.  Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine.

Authors:  J Friedman; K Ault; P Powchik
Journal:  Biol Psychiatry       Date:  1997-09-15       Impact factor: 13.382

3.  The use of multiple psychotropic medication in the treatment of mental disorders.

Authors:  K S Jacob
Journal:  Aust N Z J Psychiatry       Date:  1995-06       Impact factor: 5.744

Review 4.  Clinical uses of pimozide.

Authors:  M J Tueth; J A Cheong
Journal:  South Med J       Date:  1993-03       Impact factor: 0.954

5.  Gradient of interference by various frequencies on 60 Hz kindling behavior.

Authors:  J Gaito
Journal:  Can J Neurol Sci       Date:  1980-08       Impact factor: 2.104

Review 6.  Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.

Authors:  B Fulton; K L Goa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 7.  The relationship of pharmacology to side effects.

Authors:  D E Casey
Journal:  J Clin Psychiatry       Date:  1997       Impact factor: 4.384

Review 8.  Pharmacokinetics and drug interactions: update for new antipsychotics.

Authors:  L Ereshefsky
Journal:  J Clin Psychiatry       Date:  1996       Impact factor: 4.384

9.  Assessing depression in schizophrenia: the Calgary Depression Scale.

Authors:  D Addington; J Addington; E Maticka-Tyndale
Journal:  Br J Psychiatry Suppl       Date:  1993-12
  9 in total
  2 in total

1.  Augmentation of olanzapine in treatment-resistant schizophrenia.

Authors:  Mathias Zink
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

Review 2.  Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature.

Authors:  Constantin Tranulis; Leila Skalli; Pierre Lalonde; Luc Nicole; Emmanuel Stip
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.